24 Seconds with Tayshaun Prince

by | Feb 29, 2008 | 11 comments

Please take a second and VOTE for Detroit’s Children’s Hospital a click goes a long way for Sickle Cell. Let’s do this, Detroit’s a bit behind Houston and voting ends today.

To honor Tayshaun Prince on for his Birthday(Feb 28th), here is his 24 seconds segment.

11 Comments

  1. Ahmed

    Happy B-Day Tayshaun. We are all supporting you. Happy 10th birthday. LOL!

    Reply
  2. DetroitGirl4life

    oh yeah he gotta stay young 😀

    LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Reply
  3. DetroitGirl4life

    hey if anyone say the ’24 Seconds with Rodney Stuckey’ can someone recap on what he said ?

    LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Reply
  4. Natalie

    I have Rodney’s coming, just haven’t posted it yet.

    Reply
  5. DetroitGirl4life

    ^okay thank-you…it’s just that when i was waiting for the game to come on…my mom wanted to measure me ? then when i came back i just saw the end of it when he was saying something about Jessica Alba and i just got soo mad, lol

    LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Reply
  6. Anonymous

    i hate tayshaun ever since i seen how he really was at a meet n greet with not siging autographs for little kids and hurrying them up for pictures hes a complete ass and wouldnt mind seeing him leave..ur all fooled if u think hes a nice guy..hes not..now mcdyess ive met alot he ust to come into my store alot hes a really nice guy, but tayshaun just a jerk.

    Reply
  7. Dooley

    hey.. detroit is in the lead.

    awesome for sharing this natalie

    Reply
  8. DetroitGirl4life

    actually when i went to the game with need4sheed…tay came over and said hello and shaked my hand (i think he did it because he thought i was one of the kids that was in the kids for ‘Tay’s Town’) any tay seems really nice. But i would really want 2 meet Rodney and Amir…oh boy that would be some day.

    LET’S GO PISTONS AND LET’S GET THAT SHIP!!!!!!!!!!!!!!!!!!!!!!!!!!! 2007-2008 IT’S OUR TIME!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    ALL BOUT DETROIT BABY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

    Reply
  9. Anonymous

    I loved that. That’s the most I’ve heard Tayshaun talk since he came here,lol. I loved his expression and enthusiam. 🙂

    Reply
  10. detroit 2 hot 2 handle

    DETROIT HOSPITAL WON 🙂 Nice stuff guys!! Well done

    Reply
  11. Asclepius

    NICOSAN for the Treatment of Sickle Cell Disease

    I would like to make you aware that there is a
    non-toxic viable treatment for sickle cell in the
    world, unfortunately it is not available in the U.S..
    Through awareness there may come availability for
    those who so desperately need it. All it is going to
    take is the effort of a few individuals, patients and
    doctors to make this drug a reality in the U.S. sooner
    than later. Although this drug was developed in
    Nigeria, the man behind it, Dr. Ramesh Pandey is a
    distinguished biochemist who has worked for the
    National Cancer Institute’s (NCI) Frederick Cancer
    Research Center as a Senior Scientist, Head of the
    Chemistry Section, Abbott Pharmaceuticals and
    produced the first commercially viable generic version
    of Vancomycin for Lyphomed Inc., a Visiting Professor
    at the Waksman Institute of Microbiology at Rutgers,
    the State University of New Jersey, holds patents for
    biotechnology analysis and rare drug production
    processes. He also holds several US and international
    patents for paclitaxel and its new analogs. He is a
    member of the Editorial Board of the International
    Journal of Antibiotics and of several professional
    societies. He has been awarded several grants from
    NASA, NCI and NIH. The drug NICOSAN has been granted
    Orphan Drug Status by both the FDA and E.U..

    There is a relatively new treatment for sickle cell being
    produced in Nigeria by an American company called NICOSAN®,
    it’s proprietary name is NIPRISAN® . It was developed on
    the premise of traditional Nigerian plant based medicinal
    practices for the treatment of sickle cell disease.

    It has been tested through phase IIb clinical trials and
    found to be highly efficacious. Phase III trials have yet
    to be completed however it was approved for sale in Nigeria
    based on phase IIb trials and toxicity studies which showed
    it to be safe and non-toxic.

    Double-blind, placebo-controlled, randomised cross-over
    clinical trial of NIPRISAN® in patients with Sickle Cell
    Disorder

    http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7GVW-4DS346T-1S&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=211981d545303693affebb8c012d2cac

    Efficacy of Niprisan in the prophylactic management of
    patients with sickle cell disease

    http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VS8-43DFJCH-G&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=10528ecbab3ec7e977301fb9f2688ef6

    NIPRISAN — Nix-0699 Toxicity Studies

    http://www.biospace.com/news_story.aspx?StoryID=15890720&full=1

    Niprisan (Nix-0699) improves the survival rates of
    transgenic sickle cell mice under acute severe hypoxic
    conditions

    http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2141.2003.04536.x?journalCode=bjh

    NIPRISAN Case, Nigeria
    A Report for GenBenefit (2007)

    http://www.theparliament.com/NR/rdonlyres/F46A1A12-0A1A-41DA-9F5D-A11486CA9BFA/0/Nigerian_Case.pdf

    This drug is a major advancement in the treatment of sickle
    cell disease unfortunately it is not available in the U.S..
    Although the compound has been granted orphan drug status
    by the FDA and the regulatory body of the European Union,
    to date investigational drug applications for the approval
    process have yet to be submitted. Getting a drug approved
    in either area is extremely expensive. Until there is
    funding available to proceed with the FDA and EU
    applications it will be difficult for non-Nigerians to
    obtain the drug.

    I do say difficult but it is not impossible. If you have a
    hematologist or hemoncologist who is willing to put fourth
    the effort there are special dispensations available
    through the FDA for the importation of unapproved drugs on
    a compassionate use basis.

    “Expanded access program (EAP). EAPs are typically designed
    to provide widespread access to a drug that has proven
    efficacy in clinical trials but is still awaiting FDA
    approval. They’re similar to standard clinical trials with
    a specific treatment plan and certain FDA requirements, but
    they have looser patient eligibility criteria. More than
    23,000 U.S. cancer patients enrolled in an EAP for Iressa
    before it was FDA-approved, for example.”

    “Single patient use. This program offers an experimental
    drug to an individual patient, rather than a group. The FDA
    approves these uses on a case-by-case basis. Decisions are
    based on other treatments already available and information
    about the drug’s efficacy and potential toxicities.”

    http://www.curetoday.com/backissues/v3n3/departments/specialreport/index.html

    To date I have no knowledge that anyone has sought any
    single use or expanded access from the FDA for Nicosan.
    Unfortunately regardless of the dissemination of this
    information thus far no one has put forth the effort to
    obtain the drug for use.

    If just one person would start the ball rolling with a
    caring and concerned medical practitioner it could open up
    the drug for wide spread use by tens of thousands of
    patients across the U.S. Unfortunately thus far the general
    response I receive is that people don’t believe that their
    physician would be interested in going to this sort of
    effort nor do they themselves seem to be inclined to seek
    the use of a treatment that could potentially end their
    crises.

    There has to be at least one physician out there who has
    enough care and concern for his patients to be willing to
    put forth the effort necessary to obtain this medication
    legally. I urge anyone who is effected by sickle cell to
    approach their physicians with this information and attempt
    to obtain this treatment not only for themselves but for
    all patients who could potentially benefit from it’s use.

    We already know the benefits of the treatments available in
    the U.S. and the E.U.. In many cases they are only
    marginally effective or in the case of hydroxyurea cause
    side effects so serious that many choose not to use it as
    treatment. Here we have an opportunity to use a treatment
    that has been shown to be highly effective, eradicating
    crises in the majority of patients and reducing crises by
    50% in the most refractory cases.

    Although the clinical trial group was what the casual
    reader might interpret as quite small it is common for
    drugs which fall into the orphan drug category to use small
    sample groups. Many orphan drugs have been approved based
    on very small phase II and phase IIb clinical trials in the
    U.S. In the case of FDA fast track status, a drug may be
    approved during phase II trials if the drug shows
    significant advantage over current approved therapies for
    life threatening illness.

    Fast Track Designation is a program that, if granted, is
    designed to facilitate the development and expedite the
    review of new drugs, thereby allowing the FDA to approve
    drugs used to treat a serious condition or a
    life-threatening disease with less safety data following
    the conclusion of phase II studies, rather than phase III,
    the normal practice.

    The main criterion for a Fast Track Designated drug is the
    potential to treat a life-threatening illness or fill a
    major unmet medical need. Fast Track may be submitted with
    the IND or at any time during the clinical development of
    the drug. The Fast Track designation may allow a company’s
    application to follow Priority Review, Standard Review, or
    a Rolling Review of the application.

    http://www.fda.gov/CbER/gdlns/fsttrk.pdf

    Nicosan by Western standards is an extremely inexpensive
    drug. It is available in Nigeria without prescription at
    $23/month for adults and child doses at $18/month.

    Here is a link to the company and product website.

    http://xechemnigeria.com/products.htm

    I sincerely hope that you find this information helpful. I
    would encourage you to forward and post this information
    to any person, blog or website where persons effected by
    sickle cell anemia can have access to this information.

    Feel free to write me with any questions you may have.

    NicosanForSickleCell@yahoo.com

    Reply

Submit a Comment

Your email address will not be published.

Pistons

  • Rasheed Wallace
  • Greg Monroe
  • Andre Drummond
  • Josh Smith
  • Brandon Jennings
  • Caron Butler
  • Kentavious Caldwell-Pope
  • Jodie Meeks
  • D.J. Augustin
  • Gigi Datome
  • Spencer Dinwiddie
  • Jonas Jerebko
  • Kyle Singler
  • Tony Mitchell
  • Stan Van Gundy
  • Arnie Kander
  • Mike Abdenour
  • Tom Gores
  • Greg Kelser
  • George Blaha
  • John Mason

Pistons Past

  • Chauncey Billups
  • Rodney Stuckey
  • Brandon Knight
  • Tayshaun Prince
  • Richard Hamilton
  • Jason Maxiell
  • Tracy McGrady
  • Will Bynum
  • Austin Daye
  • Chris Wilcox
  • Dajuan Summers
  • Peyton Siva
  • Kim English
  • Terrico White
  • Josh Harrellson
  • Charlie Villanueva
  • Vernon Macklin
  • Viacheslav Kravtsov
  • Ben Gordon
  • Ben Wallace
  • Isiah Thomas
  • Maurice Cheeks
  • Lawrence Frank
  • John Kuester
  • Chuck Daly
  • Bill Laimbeer
  • Joe Dumars

Archives